Search Results - "Riely, G.J."

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 by Shaw, A.T., Riely, G.J., Bang, Y.-J., Kim, D.-W., Camidge, D.R., Solomon, B.J., Varella-Garcia, M., Iafrate, A.J., Shapiro, G.I., Usari, T., Wang, S.C., Wilner, K.D., Clark, J.W., Ou, S.-H.I.

“…In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC)…”
Get full text

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer by Hastings, K., Yu, H.A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C.A., Liu, Z., Henick, B.S., Wurtz, A., Cai, G., Plodkowski, A.J., Long, N.M., Halpenny, D.F., Killam, J., Oliva, I., Schultz, N., Riely, G.J., Arcila, M.E., Ladanyi, M., Zelterman, D., Herbst, R.S., Goldberg, S.B., Awad, M.M., Garon, E.B., Gettinger, S., Hellmann, M.D., Politi, K.

“…Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however,…”
Get full text

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation by Jänne, P.A., Rybkin, I.I., Spira, A.I., Riely, G.J., Papadopoulos, K.P., Sabari, J.K., Johnson, M.L., Heist, R.S., Bazhenova, L., Barve, M., Pacheco, J.M., Leal, T.A., Velastegui, K., Cornelius, C., Olson, P., Christensen, J.G., Kheoh, T., Chao, R.C., Ou, S.H.I.

Get full text

Investigation of patterns of nodal metastases in BRAF mutant lung cancer by McEvoy, S.H., MB BCh BAO, Halpenny, D.F., MB BCh BAO, Viteri-Jusué, A., MD, Hayes, S.A., MD, Plodkowski, A.J., MD, Riely, G.J., MD, Ginsberg, M.S., MD

“…Highlights • Axillary lymph nodes are a rare site of nodal metastases in lung cancer patients. • BRAF mutated NSCLC patients have a higher incidence of…”
Get full text

Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy? by Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Get full text

Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation? by Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Get full text

Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy? by Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Get full text

Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation? by Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Get full text

Brain Metastases in EGFR-Mutated Lung Cancer: Is Radiation Therapy Necessary? by Gerber, N, Yamada, Y, Riely, G.J, Beal, K, Yu, H, Chan, T, Rimner, A, Wu, A.J

Get full text

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1 by Kim, D, Mehra, R, Tan, D.S.W, Felip, E, Chow, L.Q.M, Camidge, D.R, Vansteenkiste, J, Sharma, S, De Pas, T, Riely, G.J, Solomon, B.J, Wolf, J, Thomas, M, Schuler, M, Liu, G, Santoro, A, Geraldes, M, Boral, A.L, Yovine, A, Shaw, A.T

Get full text

Clinical Activity of Crizotinib in Ros1-Rearranged Non-Small Cell Lung Cancer by Shaw, A., Ou, S.I., Bang, Y., Camidge, R., Solomon, B., Salgia, R., Riely, G.J., Varella-Garcia, M., Shapiro, G., Costa, D., Doebele, R., Le, L.P., Zheng, Z., Stephenson, P., Shreeve, S.M., Tye, L., Christensen, J., Wilner, K., Clark, J., Iafrate, A.

Get full text

9084 POSTER A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC) by Kim, D.W, Blackhall, F, Soria, J.C, Solomon, B, Camidge, D.R, Riely, G.J, Bottomley, A, Tassell, V, Polli, A, Shaw, A

Get full text

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib by Schoenfeld, A.J., Arbour, K.C., Rizvi, H., Iqbal, A.N., Gadgeel, S.M., Girshman, J., Kris, M.G., Riely, G.J., Yu, H.A., Hellmann, M.D.

“…Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor…”
Get full text

1054P Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer by Elkrief, A., Bowman, A., Rizvi, H., Hellmann, M., Riely, G.J., Schoenfeld, A.J., Ladanyi, M., Vanderbilt, C.M.

Get full text

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers by Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

“…MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung…”
Get full text

COVID-19 in patients with lung cancer by Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.

“…Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and…”
Get full text

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas by Schoenfeld, A.J., Rizvi, H., Bandlamudi, C., Sauter, J.L., Travis, W.D., Rekhtman, N., Plodkowski, A.J., Perez-Johnston, R., Sawan, P., Beras, A., Egger, J.V., Ladanyi, M., Arbour, K.C., Rudin, C.M., Riely, G.J., Taylor, B.S., Donoghue, M.T.A., Hellmann, M.D.

“…Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma,…”
Get full text

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing by Yu, H.A., Arcila, M.E., Hellmann, M.D., Kris, M.G., Ladanyi, M., Riely, G.J.

“…EGFR T790M is the most common mutation associated with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Baseline EGFR T790M mutations in EGFR…”
Get full text

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium by Li, B.T., Janku, F., Jung, B., Hou, C., Madwani, K., Alden, R., Razavi, P., Reis-Filho, J.S., Shen, R., Isbell, J.M., Blocker, A.W., Eattock, N., Gnerre, S., Satya, R.V., Xu, H., Zhao, C., Hall, M.P., Hu, Y., Sehnert, A.J., Brown, D., Ladanyi, M., Rudin, C.M., Hunkapiller, N., Feeney, N., Mills, G.B., Paweletz, C.P., Janne, P.A., Solit, D.B., Riely, G.J., Aravanis, A., Oxnard, G.R.

“…Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also…”
Get full text

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC by Ou, S.-H. I., Jänne, P.A., Bartlett, C.H., Tang, Y., Kim, D.-W., Otterson, G.A., Crinò, L., Selaru, P., Cohen, D.P., Clark, J.W., Riely, G.J.

“…Crizotinib is approved to treat advanced ALK-positive non-small-cell lung cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We…”
Get full text